Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 550 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nonalcoholic Fatty Liver Disease (NAFLD) Clear all
Completed Phase 2 Interventional Results available

A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

NCT04767529
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
54
States / cities
Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 13, 2026, 10:52 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT06161571
View directory record Official record
Conditions
NASH/MASH, NAFLD/MASLD
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
139
States / cities
Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 13, 2026, 10:52 AM EDT
Completed No phase listed Observational

The Visceral Adiposity Measurement and Observation Study

NCT05383456
View directory record Official record
Conditions
HIV, HIV-Infections, HIV-1-infection, HIV I Infection, HIV Lipodystrophy, HIV Infection Primary, HIV-Associated Lipodystrophy, HIV Disease Progression, Lipohypertrophy, Liver Diseases, NAFLD, NASH, Liver Fibrosis, Hepatic Fibrosis, Waist Circumference, BMI, Ectopic Fat, Liver Fat, Hepatic Steatosis
Interventions
Diagnostic Test, HIV Anti-retroviral Background Therapy
Diagnostic Test · Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Miami Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 13, 2026, 10:52 AM EDT
Not yet recruiting Phase 2 Interventional

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

NCT03867487
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
Interventions
Empagliflozin 10 MG, Placebo Oral Tablet
Drug
Lead sponsor
Justin Ryder
Other
Eligibility
12 Years to 20 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 13, 2026, 10:52 AM EDT
Withdrawn Not applicable Interventional

Evaluating the Efficacy of CPAP Therapy for the Treatment of Fatty Liver

NCT01849081
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
CPAP, LIfestyle
Device · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 13, 2026, 10:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults

NCT06121999
View directory record Official record
Conditions
Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
Interventions
Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications
Behavioral
Lead sponsor
Grand Valley State University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Wyoming, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 13, 2026, 10:52 AM EDT
Active, not recruiting No phase listed Observational

Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV

NCT04795219
View directory record Official record
Conditions
NAFLD, NAFLD-HIV, Hiv
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
8
States / cities
Tuscaloosa, Alabama • La Jolla, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 13, 2026, 10:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Leptin Receptors in NASH

NCT00583999
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Metabolic Syndrome
Interventions
no interventions, only regular blood-draw
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 13, 2026, 10:52 AM EDT
Completed No phase listed Observational

Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)

NCT02363309
View directory record Official record
Conditions
Fatty Liver
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 13, 2026, 10:52 AM EDT
Recruiting No phase listed Observational

Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis

NCT05720663
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Standard of care
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 13, 2026, 10:52 AM EDT
Completed Phase 2 Interventional

IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT05989711
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
Pemvidutide, Placebo
Drug
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 13, 2026, 10:52 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

NCT02927184
View directory record Official record
Conditions
Hyperlipidemia, NAFLD
Interventions
VK2809, Placebo
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Chandler, Arizona • Garden Grove, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 13, 2026, 10:52 AM EDT
Completed No phase listed Observational

NAFLD Pediatric Database 2

NCT01061684
View directory record Official record
Conditions
Liver Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
2 Years to 17 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 13, 2026, 10:52 AM EDT
Withdrawn No phase listed Observational

Natural History of Non Alcoholic Fatty Liver Disease and Predictors of Advanced Fibrosis

NCT05050721
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
CT imaging
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Timeline
2019 – 2021
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 13, 2026, 10:52 AM EDT
Terminated Phase 2 Interventional Results available

Gemcabene for the Treatment of Pediatric NAFLD

NCT03436420
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Gemcabene
Drug
Lead sponsor
Emory University
Other
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 13, 2026, 10:52 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

NCT05463796
View directory record Official record
Conditions
Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
Interventions
Samples
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 13, 2026, 10:52 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT02704403
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions
Elafibranor, Placebo
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
2,157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
153
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 13, 2026, 10:52 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

NCT04771273
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Survodutide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
36
States / cities
Huntsville, Alabama • Coronado, California • Huntington Park, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 13, 2026, 10:52 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

NCT04929483
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
BIO89-100, Placebo
Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
88
States / cities
Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 13, 2026, 10:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease

NCT00714129
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Diabetes
Interventions
Dietary intervention (calorie restricted diet)
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Vallejo, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 13, 2026, 10:52 AM EDT
Completed Not applicable Interventional Results available

Noninvasive Biomarkers of Metabolic Liver Disease 1.1

NCT04828551
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Interventions
Ultrasound based shear wave speed and fat quantification methods, Blood collection, Physical measurements, Clinical history and medication reviews
Device · Diagnostic Test · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
San Diego, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 13, 2026, 10:52 AM EDT
Completed Phase 1 Interventional Results available

2-Week Study In People With Nonalcoholic Fatty Liver Disease

NCT03513588
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions
Placebo, PF-06865571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Anaheim, California • New Haven, Connecticut • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 13, 2026, 10:52 AM EDT
Suspended Phase 3 Interventional Results available

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

NCT04104321
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Aramchol free acid, Placebo
Drug
Lead sponsor
Galmed Research and Development, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Miami, Florida • Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 13, 2026, 10:52 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions

NCT06932289
View directory record Official record
Conditions
NAFLD (Nonalcoholic Fatty Liver Disease)
Interventions
Mediterranean diet (MED), high-fat/low carb diet (HF/LC), and low-fat diet (LF), The integrated sweat sensor and vascular sensor (wearable), continuous glucose monitor (CGM)
Dietary Supplement · Device
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 13, 2026, 10:52 AM EDT